Novartis
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novartis and other ETFs, options, and stocks.About NVS
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies.
NVS Key Statistics
NVS News
H.C. Wainwright reiterates a Buy rating on Halozyme (HALO) with a $115 price target after Novartis (NVS) signed an option and license agreement with Alteogen co...
Alteogen announced that it has entered into an option and license agreement with Novartis (NVS) for the development and commercialization of subcutaneous, SC, p...
Analyst Thibault Boutherin of Morgan Stanley maintained a Buy rating on Novartis AG, retaining the price target of CHF135.00. Thibault Boutherin has given his B...
Analyst ratings
41%
of 29 ratingsMore NVS News
Novartis AG (NYSE:NVS) stock climbed Tuesday after the Swiss drugmaker reported positive Phase 3 results for remibrutinib in relapsing multiple sclerosis. Remi...
After Novartis (NVS) announced topline data from the REMODEL-1/-2 trials of remibrutinib in relapsing multiple sclerosis, H.C. Wainwright analyst Emily Bodnar b...
Novartis (NVS) stock rose about 6% at the time of writing on Tuesday, after the Swiss drugmaker reported positive results from two late-stage trials of remibrut...
Technology Why Novartis Just Surged 6%, Eyeing A Breakout Licensing Novartis (NVS) stock surged early Tuesday after its experimental multiple sclerosis treatmen...
Two trials for relapsing multiple sclerosis met their primary goal by showing reduced relapse rates. Fabrice Coffrini / Agence France-Presse / Getty Images Nov...
An announcement from Novartis ( (NVS) ) is now available. On September 1, 2026, Novartis reported positive topline Phase III results for remibrutinib in the RE...
Novartis (NVS) announced positive topline results from its Phase III Remodel-1/-2 trials of remibrutinib in relapsing multiple sclerosis. Remibrutinib, a highly...
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.